Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic. - Wikidata - awgldk - TriplyDB

Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic.

Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic.

http://www.wikidata.org/entity/Q30394995

about

Incidence of H1N1 2009 virus infection through the analysis of paired plasma specimens among blood donors, France Prevalence of 2009 pandemic influenza A (H1N1) virus antibodies, Tampa Bay Florida--November-December, 2009 Seroprevalence of pandemic influenza H1N1 in Ontario from January 2009-May 2010 Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries.Pandemic influenza A/H1N1pdm in Italy: age, risk and population susceptibility.Pre- and postpandemic estimates of 2009 pandemic influenza A(H1N1) seroprotection to inform surveillance-based incidence, by age, during the 2013-2014 epidemic in Canada.Study on age-dependent pre-existing 2009 pandemic influenza virus T and B cell responses from Chinese population Age-related changes in memory and effector T cells responding to influenza A/H3N2 and pandemic A/H1N1 strains in humans.Did modeling overestimate the transmission potential of pandemic (H1N1-2009)? Sample size estimation for post-epidemic seroepidemiological studies Prevalence of antibodies to 2009 pandemic influenza A (H1N1) virus in German adult population in pre- and post-pandemic period.The age-specific cumulative incidence of infection with pandemic influenza H1N1 2009 was similar in various countries prior to vaccination Can interactions between timing of vaccine-altered influenza pandemic waves and seasonality in influenza complications lead to more severe outcomes?High incidence of severe influenza among individuals over 50 years of age.Seroprevalence and severity of 2009 pandemic influenza A H1N1 in Taiwan.Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine.High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults.Seroprevalence study of antibodies against influenza A(H1N1) 2009 virus after the second pandemic wave in Slovenia.Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients.AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans.Prevalence of seropositivity to pandemic influenza A/H1N1 virus in the United States following the 2009 pandemic H3N2v and other influenza epidemic risk based on age-specific estimates of sero-protection and contact network interactions.Factors associated with post-seasonal serological titer and risk factors for infection with the pandemic A/H1N1 virus in the French general population.H1N1 pandemic: clinical and epidemiologic characteristics of the Canadian pediatric outbreak.Detecting signals of seasonal influenza severity through age dynamics Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories.A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season.Patterns of spread of influenza A in Canada.Assessment of Baseline Antibodies to Pandemic Influenza A/H1N1/2009 Virus in Ogbomoso, Oyo State, Nigeria.

P2860

Q28730980-5BEBAFBD-67A8-4CCB-99B6-B037F6BF4504 Q28741061-F157B70B-0DE6-4457-86A0-8D10D8608C2D Q28742786-388D9516-7A10-442B-B153-B0118471DFF0 Q30223476-6357CBD9-632C-41A2-A3CB-3B3E7DDAA93C Q30354383-D214602A-61F3-4089-84A6-36AD31A8703E Q30364076-3D9BFF95-0313-4E03-89B8-2176D2CD9ADD Q30398477-3172B702-A40F-4685-92B2-B685DF76950C Q30400174-6E451443-E494-4B2D-8B79-92228358CBE2 Q30401351-8724ABB3-D0C3-4851-A619-58D4D1D1D29F Q30404184-B7D97E85-8A02-48A2-9032-6AF9F57472C7 Q30406109-5ECD3F40-AFDA-4E5B-9516-A64A47E8BCD0 Q30406645-AC116B71-2A32-4407-ABC1-98FEF837FD85 Q30406838-4F836792-5B9E-4B16-A8EA-9AE3E39B8CDA Q30406971-0775306C-F043-4AAA-BCB4-BF5475D18F00 Q30412266-212123A3-6807-4B6D-9FC7-91E859652EFD Q30412595-D508ED2B-B867-4252-BEEF-7D06B2D60430 Q30412979-61E187E0-CEAB-4D42-BC5E-263DC45A0648 Q30421507-6A7E29D6-52FA-40C5-A80B-967D1B546398 Q30421821-2F53A1C2-64F9-408D-A0C1-9162AA1B55AC Q30423135-7E7F9E75-EFBD-4EA7-8A55-DF58F72D56C6 Q30426038-5EB3C13B-2EFF-4A48-9DC6-BF1E6F7085E3 Q30429711-B700B660-656B-4E4D-A4F3-EB44DA3CCF7C Q30431681-B460BBBE-E48E-407F-9D62-A4127F9F22A6 Q35881219-3C01C809-76BE-4B20-9129-B28A8B0E1134 Q36665657-DC495F62-0EED-4E52-9B2A-DEEBC0BDDFDC Q47843797-5572473B-D97E-4C55-8F88-3710E2E4F67D Q51165360-AC4906FB-72A6-41C4-A54A-06D1D7B4FF2E Q53690476-C7F77CE9-784B-4064-9E7E-8E6861B68701

P2860

Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic.

http://www.wikidata.org/entity/Q30394995

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic.

@ast

Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic.

@en

type

label

Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic.

@ast

Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic.

@en

prefLabel

Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic.

@ast

Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic.

@en

P1433

Q30394995-D8AB87A8-FEE3-498A-8455-4022D0CBA54C

P1476

Q30394995-2B278A87-8B7D-4EDF-B03F-9EC8EAB58F75

P2093

Q30394995-448F7DAE-67E2-4D1A-A90A-BB4A1811241A

Q30394995-60240052-B784-494F-9E9B-D646975E101F

Q30394995-8573E752-054E-47E2-A24D-383B9BE55464

Q30394995-8E313ECA-CB85-4B0C-96E0-023240DB3B37

Q30394995-9EC0C381-5689-492F-9C1E-70C4B9E15F87

Q30394995-BBB1CE7C-8338-426D-A913-6DA437CC0BBE

Q30394995-F1814060-2168-4F41-AE5F-5BCE4CEDC90D

P2860

Q30394995-331C625B-3E5E-4620-AE65-D4BA7952AD60

Q30394995-5510F915-47F2-4A24-8509-1008941BBD25

Q30394995-5ADE7F99-52A4-4326-93C9-51269D1A72FA

Q30394995-6C24DB03-A609-4161-918F-0D63F74BD745

Q30394995-701C9ACD-7FD4-4762-82F6-B2462B528D06

Q30394995-74721E73-DC50-44AB-9B0B-FA6AC8318ECE

Q30394995-79A95B68-643B-4F7B-9DCC-F9739DD8EC0C

Q30394995-80FCA670-F514-4CAF-A5B5-BF454D1AC3EF

Q30394995-85788A86-8524-4E73-A816-EAD598F326A6

Q30394995-86FC4D51-B403-4796-A926-643100B3D4D0

P304

Q30394995-FA4A5D4F-13E3-4A4E-A390-305B15687824

P31

Q30394995-98CB28D6-B9B2-4255-8D8D-5A360CEDDA6A

P356

Q30394995-DD04244E-0964-44D7-8193-EAA738175C90

P407

Q30394995-FB075EEA-63D5-4CA1-89C3-B8B6BC183551

P433

Q30394995-CEF3F479-39B0-4616-B0DE-7EC8EAD45C05

P478

Q30394995-A2DCEF99-7915-46F5-83C4-EDB8B26791BD

P50

Q30394995-437F3304-AA4C-42FF-BEBA-3DD75F96E42B

Q30394995-5020754B-333A-4D1A-80FF-C43F48CD8E1C

Q30394995-5727E206-74FC-4686-B752-F87DA4556D0B

Q30394995-784D1387-2C80-47D5-84A8-38586BC91432

P577

Q30394995-24A2B840-9748-4A91-85F6-31A3B3452FDC

P5875

Q30394995-42361A1A-64FE-4963-91B3-B5157AB57A8B

P698

Q30394995-BD4817BE-96D3-462D-929E-022FD1443DE0

P921

Q30394995-88C63D4E-3E0D-47EB-A24A-06C52DE27A77

P932

Q30394995-64E6CC0D-3E55-4901-A4DC-6E4ADB20DC9E

P356

P1433

Canadian Medical Association Journal

P1476

Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic.

@en

P2093

Dale Purych

http://www.w3.org/2001/XMLSchema#string

Danuta M Skowronski

http://www.w3.org/2001/XMLSchema#string

Janet E McElhaney

http://www.w3.org/2001/XMLSchema#string

Jennifer Gardy

http://www.w3.org/2001/XMLSchema#string

Martin Petric

http://www.w3.org/2001/XMLSchema#string

Suzana Sabaiduc

http://www.w3.org/2001/XMLSchema#string

Tracy Chan

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study

Pandemic versus epidemic influenza mortality: a pattern of changing age distribution

Risk of severe outcomes among patients admitted to hospital with pandemic (H1N1) influenza

Initial human transmission dynamics of the pandemic (H1N1) 2009 virus in North America.

Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009.

Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009.

The transmissibility and control of pandemic influenza A (H1N1) virus.

Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California.

Estimation of the reproductive number and the serial interval in early phase of the 2009 influenza A/H1N1 pandemic in the USA.

Estimated epidemiologic parameters and morbidity associated with pandemic H1N1 influenza.

P304

1851-1856

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1503/CMAJ.100910

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

182

http://www.w3.org/2001/XMLSchema#string

P50

Naveed Zafar Janjua

Travis Salway Hottes

Gaston De Serres

David M Patrick

P577

2010-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47459467

http://www.w3.org/2001/XMLSchema#string

P698

20956500

http://www.w3.org/2001/XMLSchema#string

P921

P932

2988533

http://www.w3.org/2001/XMLSchema#string